Procalcitonin in peritoneal dialysis - A useful marker of inflammation?

Peritoneal Dialysis International

Volumn 25, Issue 5, 2005, Pages 441-444

  Alscher, Dominik M ^a   Mettang, Thomas ^b  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ADRENOMEDULLIN; ALBUMIN; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; FERRITIN; FIBRONECTIN; GAMMA INTERFERON; HAPTOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; OROSOMUCOID; PHOSPHOLIPASE A2; PREALBUMIN; PROCALCITONIN; SERUM AMYLOID A; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HEMODIALYSIS; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE STRUCTURE; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; NONHUMAN; NOTE; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ULTRAFILTRATION;

EID: 26844541699     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500507     Document Type: Note

References (38)

1. Opatrna S, Klaboch J, Opatrny Jr. K, Holubec Jr. L, Tomsu M, Sefrna F, et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int 2005; 25:470-2.
2. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-25.
3. Friedman J, Raisz LG. Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science 1965; 150:1465-7.
4. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134:49-55.
5. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-8.
6. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40:1250-6.
7. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998; 24:680-4.
8. Nylen ES, Al Arifi A, Becker KL, Snider RH Jr., Alzeer A. Effect of classic heatstroke on serum procalcitonin. Crit Care Med 1997; 25:1362-5.
9. Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, et al. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scond J Immunol 2005; 61:180-6.
10. Mitaka C. Clinical Laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 2005; 351(1-2):17-29.
11. Whicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001; 38(Pt 5): 483-93.
12. Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002; 15:297-301.
13. Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29:579-83.
14. Oberhoffer M, Karzai W, Meier-Hellmann A, Bogel D, Fassbinder J, Reinhart K. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med 1999; 27:1814-18.
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
16. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N YAcad Sci 1982; 389:406-18.
17. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251-5.
18. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35:469-76.
19. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
20. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150:2007-17.
21. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2:416-22.
22. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19:761-5.
23. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
24. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53:452-9.
25. Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, et al. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 1996; 49:236-43.
26. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417-22.
27. Topley N. In vitro biocompatibitity of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int 1997; 17:42-7.
28. Topley N, Williams JD. Effect of peritoneal dialysis on cytokine production by peritoneal cells. Blood Purif 1996; 14:188-97.
29. Witowski J, Jorres A, Coles GA, Williams JD, Topley N. Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 rn RNA. Kidney Int 1996; 50:1212-23.
30. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimburger O, Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24: 327-39.
31. Chung SH, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16:2240-5.
32. Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13:962-8.
33. Blake PG, Abraham G, Sombolos K, Izatt S, Weissgarten J, Ayiomamitis A, et al. Changes in peritoneal membrane transport rates in patients on long term CAPD. Adv Perit Dial 1989; 5:3-7.
34. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
35. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-17.
36. Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003; 144:5578-84.
37. Muller B, Christ-Crain M, Nylen ES, Snider R, Becker KL. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 2004; 39:1867-8.
38. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001; 18:79-87.